35.27

6.85% 2.26

Pre-market: 36.15 0.88 +2.50%

Tyra Biosciences Inc (TYRA)

Overview News Price History Option Chain Financials Discussions Forecast

Tyra Biosciences Inc stock is traded at $35.27, with a volume of 6.15M. It is up +6.85% in the last 24 hours and up +14.62% over the past month. Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Previous Close:

$33.01

Open:

$32

24h Volume:

6.15M

Relative Volume:

8.30

Market Cap:

$1.88B

Revenue:

Net Income/Loss:

$-83.74M

P/E Ratio:

-21.91

EPS:

-1.61

Net Cash Flow:

$-64.98M

1W Performance:

+2.23%

1M Performance:

+14.62%

6M Performance:

+190.53%

1Y Performance:

+222.10%

1-Day Range:

$30.47

$35.96

1-Week Range:

$30.10

$35.96

52-Week Range:

$6.42

$35.96

Tyra Biosciences Inc Stock (TYRA) Company Profile

Name

Tyra Biosciences Inc

Sector

Healthcare (1106)

Industry

Biotechnology (621)

Phone

(619) 728-4760

Address

2656 STATE STREET, CARLSBAD

Employee

Twitter

Next Earnings Date

2025-03-26

Latest SEC Filings

TYRA's Discussions on Twitter

Compare TYRA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TYRA Tyra Biosciences Inc	35.27	1.76B	0	-83.74M	-64.98M	-1.61
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-10-26	Initiated	William Blair	Outperform
Jan-28-26	Initiated	Barclays	Overweight
Sep-03-25	Initiated	Raymond James	Strong Buy
May-21-25	Resumed	Piper Sandler	Overweight
Jan-07-25	Initiated	UBS	Buy
Oct-18-24	Upgrade	BofA Securities	Neutral → Buy
Aug-15-24	Initiated	Piper Sandler	Overweight
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral
Jun-30-23	Initiated	Wedbush	Outperform
Feb-03-23	Initiated	Oppenheimer	Outperform
Jun-23-22	Initiated	H.C. Wainwright	Buy
Mar-08-22	Upgrade	Jefferies	Hold → Buy
Nov-08-21	Downgrade	Jefferies	Buy → Hold
Oct-11-21	Initiated	BofA Securities	Buy
Oct-11-21	Initiated	Cowen	Outperform
Oct-11-21	Initiated	Jefferies	Buy

View All

Tyra Biosciences Inc Stock (TYRA) Latest News

04:30 AM

Tyra Biosciences (NASDAQ:TYRA) Sets New 1-Year HighHere's Why - MarketBeat

04:30 AM

Mar 04, 2026

Tyra Bioscience Raises $126 Million in Block Share Sale - TipRanks

Mar 04, 2026

Tyra Biosciences announces $126 million stock sale in block transaction By Investing.com - Investing.com Australia

Mar 04, 2026

Tyra Biosciences announces $126 million stock sale in block transaction - Investing.com

Mar 04, 2026

According to the latest filing from the U.S. Securities and Exchange Commission (SEC), biotechnology company Tyra Biosciences has reached an agreement to privately issue 4 million common shares to a major investment management firm. - Bitget

Mar 04, 2026

Tyra Biosciences agreed to issue 4 million shares at $31.50 per share to a large investment management firmSEC filing - marketscreener.com

Mar 04, 2026

Tyra Biosciences Agreed To Issue 4 Million Shares At $31.50 Per Share To A Large Investment Management FirmSEC Filing - TradingView

Mar 04, 2026

Tyra Bios to sell 4.0M shares at $31.50 in $126M ATM block transaction - TradingView

Mar 04, 2026

Tyra Biosciences stock reaches all-time high at 35.75 USD - Investing.com

Mar 04, 2026

Tyra Biosciences stock reaches all-time high at 35.75 USD By Investing.com - Investing.com Canada

Mar 04, 2026

Tyra Biosciences (NASDAQ:TYRA) Shares Down 6.4%Here's What Happened - MarketBeat

Mar 04, 2026

TYRA: Oral Dabogratinib targets blockbuster potential in UTUC, NMIBC, and achondroplasia with pivotal data ahead - TradingView

Mar 04, 2026

TYRA: Oral dabogratinib targets blockbuster opportunities in UTUC, NMIBC, and achondroplasia - TradingView

Mar 04, 2026

Mar 03, 2026

Did Deeper Losses and Dabogratinib Progress Just Shift Tyra Biosciences' (TYRA) Investment Narrative? - Yahoo Finance

Mar 03, 2026

Oppenheimer Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛

Mar 03, 2026

H.C. Wainwright reiterates Tyra Biosciences stock rating at buy By Investing.com - Investing.com Canada

Mar 03, 2026

Tyra Biosciences (NASDAQ: TYRA) maps FGFR oncology and achondroplasia pipeline - Stock Titan

Mar 02, 2026

Tyra Biosciences (Nasdaq: TYRA) boosts R&D and outlines 2026 trial catalysts - Stock Titan

Mar 02, 2026

Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights - PR Newswire

Mar 02, 2026

Tyra Biosciences Narrows Dabogratinib Focus, Teases Mid-Year NMIBC and 2H Achondroplasia Data - Yahoo Finance

Mar 02, 2026

Mar 01, 2026

TYRATyra Biosciences, Inc. Latest Stock News & Market Updates - Stock Titan

Mar 01, 2026

Nasdaq Moves: What are the risks of holding Tyra Biosciences Inc2025 Market WrapUp & Stepwise Trade Execution Plans - baoquankhu1.vn

Mar 01, 2026

TYRA SEC FilingsTyra Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 01, 2026

Feb 28, 2026

Aug Swings: Is Tyra Biosciences Inc stock undervalued right nowMarket Risk Report & Scalable Portfolio Growth Methods - baoquankhu1.vn

Feb 28, 2026

CEO Change: Is Tyra Biosciences Inc stock undervalued right nowPortfolio Growth Summary & Low Drawdown Investment Strategies - baoquankhu1.vn

Feb 28, 2026

Tyra Biosciences (TYRA) Valuation Under Review After ASCO Catalysts And Positive Analyst Attention - Sahm

Feb 28, 2026

TYRA Should I Buy - Intellectia AI

Feb 28, 2026

Feb 27, 2026